RT Journal Article
SR Electronic
T1 A scalable serology solution for profiling humoral immune responses to SARS-CoV-2 infection and vaccination
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.25.21265476
DO 10.1101/2021.10.25.21265476
A1 Colwill, Karen
A1 Galipeau, Yannick
A1 Stuible, Matthew
A1 Gervais, Christian
A1 Arnold, Corey
A1 Rathod, Bhavisha
A1 Abe, Kento T
A1 Wang, Jenny H
A1 Pasculescu, Adrian
A1 Maltseva, Mariam
A1 Rocheleau, Lynda
A1 Pelchat, Martin
A1 Fazel-Zarandi, Mahya
A1 Iskilova, Mariam
A1 Barrios-Rodiles, Miriam
A1 Bennett, Linda
A1 Yau, Kevin
A1 Cholette, François
A1 Mesa, Christine
A1 Li, Angel X
A1 Paterson, Aimee
A1 Hladunewich, Michelle A
A1 Goodwin, Pamela J
A1 Wrana, Jeffrey L
A1 Drews, Steven J
A1 Mubareka, Samira
A1 McGeer, Allison J
A1 Kim, John
A1 Langlois, Marc-André
A1 Gingras, Anne-Claude
A1 Durocher, Yves
YR 2022
UL http://medrxiv.org/content/early/2022/02/26/2021.10.25.21265476.abstract
AB OBJECTIVES Antibody testing against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been instrumental in detecting previous exposures and analyzing vaccine-elicited immune responses. Here, we describe a scalable solution to detect and quantify SARS-CoV-2 antibodies, discriminate between natural infection- and vaccination-induced responses, and assess antibody-mediated inhibition of the spike-angiotensin converting enzyme 2 (ACE2) interaction.METHODS We developed methods and reagents to detect SARS-CoV-2 antibodies by enzyme-linked immunosorbent assay (ELISA). The main assays focus on the parallel detection of immunoglobulin (Ig)Gs against the spike trimer, its receptor binding domain (RBD), and nucleocapsid (N). We automated a surrogate neutralization (sn)ELISA that measures inhibition of ACE2-spike or -RBD interactions by antibodies. The assays were calibrated to a World Health Organization reference standard.RESULTS Our single-point IgG-based ELISAs accurately distinguished non-infected and infected individuals. For seroprevalence assessment (in a non-vaccinated cohort), classifying a sample as positive if antibodies were detected for ≥ 2 of the 3 antigens provided the highest specificity. In vaccinated cohorts, increases in anti-spike and -RBD (but not -N) antibodies are observed. We present detailed protocols for serum/plasma or dried blood spots analysis performed manually and on automated platforms. The snELISA can be performed automatically at single points, increasing its scalability.CONCLUSIONS Measuring antibodies to three viral antigens and identify neutralizing antibodies capable of disrupting spike-ACE2 interactions in high-throughput enables large-scale analyses of humoral immune responses to SARS-CoV-2 infection and vaccination. The reagents are available to enable scaling up of standardized serological assays, permitting inter-laboratory data comparison and aggregation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe acknowledge support from Ontario Together and funding from the Canadian Institutes of Health Research (CIHR; #VR1-172711, GA1-177703 and #439999) and the COVID-19 Immunity Task Force (CITF). We also acknowledge financial support from the NRC Pandemic Response Challenge Program. Funding for initial assay development in the Gingras lab was provided through generous donations from the Royal Bank of Canada and the Krembil Foundation to the Sinai Health System Foundation. The robotics equipment used is housed in the Network Biology Collaborative Centre at the LTRI, a facility supported by the Canada Foundation for Innovation, the Ontario Government, and Genome Canada and Ontario Genomics (OGI-139). Assay development in the Langlois lab and the purchase of robotic equipment was supported by a grant from the CIHR (#VR2-172722 and VS2 - 175569) and supplemental funding from the CITF. Kento T Abe was a recipient of an Ontario Graduate Scholarship and is supported by a CIHR CGS-D studentship. Yannick Galipeau is supported by a CIHR CGS-M studentship. Mariam Maltseva holds a Queen Elizabeth II Graduate Scholarship in Science and Technology (QEII-GSST). Anne-Claude Gingras is the Canada Research Chair in Functional Proteomics, and Marc-Andre Langlois, Anne-Claude Gingras, Jeffrey Wrana, and Samira Mubareka are members of CoVaRR-Net, the CIHR Coronavirus Variants Rapid Response Network.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Research Ethics Board of Mount Sinai Hospital (Toronto, ON) gave ethics approval for performing ELISA assays with samples collected across several studies (study number: #20-0078-E). The Research Ethics Board of Mount Sinai Hospital also gave ethics approval for sample collection and analysis (studies #02-0118-U/05-0016-C, #01-0138-U, #20-0144-A, #21-0049-E and #01-0347-U). The Research Ethics Board of the Unity Health Network (Toronto, ON) gave ethics approval for sample collection and analysis (study #20-044). The Research Ethics Board of Sunnybrook Health Sciences Centre gave ethics approval for sample collection and analysis (study #4814). The British Columbia Childrens Hospital Biobank (BCCHB) in Vancouver, BC, Canada gave approval sample collection and analysis (REB#: H-07-20-6009). The University of Ottawa gave ethics approval for sample collection and analysis (REB # H-04-20-5727, # H-11-20-6172 and REB # H-09-20-6135). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis is a methods development manuscript. REAGENT ACCESS: The reagents produced by the NRC and qualified as reference materials (SMT1-1, N and hACE2-BAP) are available through the Metrology Research Centre Virtual Store (Virtual Store - National Research Council Canada: Products in Category Proteins (nrc-cnrc.gc.ca)). A limited panel of matched plasma and DBS is available upon request